GtoPdb Ligand ID: 9928

Synonyms: XC-302 | XC302
Compound class: Synthetic organic
Comment: Puquitinib is an orally active, PI3 kinase inhibitor that induces autophagy by inhibiting the PI3K/AKT/mTOR signaling pathway. Puquitinib is selective for p110δ relative to other PI3K class I enzymes. It is a clinical lead developed for antitumour activity [3].
Puquitinib is a 'pseudo' INN, that takes the form of an INN, but has not been submitted to the World Health Organisation for ratification.
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 4
Topological polar surface area 91.41
Molecular weight 317.14
XLogP 2.71
No. Lipinski's rules broken 0
Canonical SMILES c1cnc2c(c1)cc(cc2)Nc1nc(NC2CC2)c2c(n1)nc[nH]2
Isomeric SMILES c1cnc2c(c1)cc(cc2)Nc1nc(NC2CC2)c2c(n1)nc[nH]2
InChI InChI=1S/C17H15N7/c1-2-10-8-12(5-6-13(10)18-7-1)22-17-23-15-14(19-9-20-15)16(24-17)21-11-3-4-11/h1-2,5-9,11H,3-4H2,(H3,19,20,21,22,23,24)
1. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ et al.. (2010)
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
Blood, 116 (12): 2078-88. [PMID:20522708]
2. So L, Fruman DA. (2012)
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.
Biochem. J., 442 (3): 465-81. [PMID:22364281]
3. Xie C, He Y, Zhen M, Wang Y, Xu Y, Lou L. (2017)
Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia.
Cancer Sci., 108 (7): 1476-1484. [PMID:28418085]
4. Yang H, Wang Y, Zhan J, Xia Y, Sun P, Bi XW, Liu PP, Li ZM, Li S, Zou BY et al.. (2015)
Puquitinib mesylate, an inhibitor of phosphatidylinositol 3-kinase p110δ, for treating relapsed or refractory non-Hodgkin's lymphoma.
Oncotarget, 6 (41): 44049-56. [PMID:26510909]